Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT06814067 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma HNSCC

Interventions

DRUG: Pembrolizumab
DRUG: Ivonescimab
PROCEDURE: Surgery
RADIATION: Adjuvant radiotherapy

Sponsor

Fudan University

Collaborators

[object Object]